SkinBit Raises $6M for AI Skin Cancer Imaging Platform

SkinBit has raised $6M in pre-seed funding to expand its full-body dermoscopic imaging platform for skin cancer screening. The Los Angeles-area healthcare technology company attracted Boost VC, Cleo Capital, Manna Ventures and Profluent Capital, alongside Lyft co-founder Logan Green and 9 board-certified dermatologists. No lead investor was publicly designated.

SkinBit plans to use the $6M to bring its first imaging locations online, refine its Sentinel imaging system and begin building the longitudinal dataset behind its platform. The company is targeting 3 operational locations in 2026 and 15 by the end of 2027.

The interesting part is not another healthcare AI company attaching AI to an examination room and waiting for applause. SkinBit is building around a less glamorous but potentially more durable asset: memory. Its system creates standardized images of a patient’s skin, compares those images over time and puts a board-certified dermatologist at the end of the process.

That distinction matters. Skin cancer screening is partly a problem of seeing what is there. Longitudinal imaging turns it into a problem of seeing what changed.

What Happened

SkinBit’s $6M pre-seed round gives Founder and CEO Jonathan Benassaya and the SkinBit team capital to move from product development toward physical deployment.

The investor group is unusually relevant to the product. Alongside Boost VC, Cleo Capital, Manna Ventures and Profluent Capital, 9 board-certified dermatologists invested in SkinBit. For a company sitting at the intersection of medical imaging, computer vision in healthcare and clinical judgment, physician participation carries a different kind of signal than another logo on a financing slide.

SkinBit’s leadership combines technology and medicine. Jonathan Benassaya is Founder and CEO. Fellow Co-Founders include Bill Dower, PhD, CTO; Dr. Justin Ko, MD, MBA, Medical Advisor; Manuel Colom, Patient Experience; and Ilya Novoselskiy, Advisor. Dr. Sancy Leachman, MD, PhD, serves as CMO, while Heather Vandenberghe works in Marketing.

Jonathan Benassaya’s reason for building SkinBit is personal. A routine dermatology appointment in 2020 discovered melanoma beneath Jonathan Benassaya’s mask. Stanford surgeons initially planned extensive facial reconstruction, but an alternative procedure ultimately preserved 85%–90% of the tissue originally marked for removal.

That is a brutal way to discover product-market motivation.

Why SkinBit Is Building a Longitudinal Skin Record

SkinBit’s Sentinel platform is designed around an approximately 20-minute imaging session using high-resolution, cross-polarized photography across 15 anatomical regions, supplemented by dermoscopic close-ups of notable marks.

Computer vision organizes the images and supports comparisons over time. A board-certified dermatologist reviews the images and metadata, with written assessments typically delivered within 48 hours.

The division of labor is important. SkinBit does not position its software as the final clinical decision-maker. The imaging system documents the skin, software helps identify and organize changes, and licensed dermatologists perform screening and diagnosis.

That architecture is less theatrical than telling the world an algorithm has become a doctor. It may also be considerably more useful.

SkinBit reports that its AI achieved 95% sensitivity and 97% specificity in its testing environment. Those figures are company-reported performance metrics, not presented here as independent clinical validation. SkinBit is also developing millimeter-wave imaging intended eventually to look beneath the skin’s surface.

The longer-term asset, however, may be the dataset created every time a patient returns. A photograph captures a moment. A standardized sequence creates history.

Why the Distribution Model Matters

SkinBit is not planning to solve healthcare distribution by opening an expensive nationwide chain of standalone clinics. Its hub-and-spoke strategy places imaging centers inside dermatology practices, longevity clinics, med spas and wellness locations.

Approximately 220 sq. ft. can be converted into a SkinBit imaging center. SkinBit supplies the equipment, standardized imaging environment and dermatologist review services. Partners provide physical space and patient access.

That changes the economics of expansion.

Instead of asking patients to discover an entirely new healthcare destination, SkinBit can enter locations where relevant consumers already spend time and money. Instead of asking partners to invent a new clinical service from scratch, SkinBit supplies the infrastructure.

The early demand signal deserves attention. SkinBit reports more than 5,000 people on its waitlist and more than 20 prospective partner locations in active pipeline discussions, achieved with $0 in paid marketing.

Venture capital likes growth. Operators should pay closer attention to growth that did not have to be rented from an advertising platform.

Market Context: Skin Cancer Has a Data Problem

SkinBit estimates its U.S. market opportunity at $20B, based on roughly 130M Americans with a history of or elevated risk for skin cancer. The $20B figure is SkinBit’s estimate rather than an independent DevCuration market calculation.

The clinical stakes are substantial. According to the American Cancer Society, basal and squamous cell skin cancers are the most common cancers in the U.S. SkinBit also cites American Cancer Society data showing melanoma has a 99% 5-year relative survival rate when detected at a localized stage.

That creates an unusual preventive healthcare technology problem. The objective is not simply producing another image with more pixels. The economic and clinical value comes from establishing a reliable baseline, returning to it and identifying meaningful change.

Healthcare has spent years collecting isolated snapshots in disconnected systems. SkinBit is betting that dermatology becomes more useful when the record behaves more like a timeline.

What the $6M Signals

SkinBit’s financing reflects a broader shift in healthcare AI away from pure software demonstrations and toward systems combining physical infrastructure, proprietary data creation and human clinical oversight.

That combination is harder to scale than shipping another chatbot. It can also be harder to copy.

Each SkinBit location potentially becomes both a service point and a data-generation node. Each repeat visit can increase the depth of a patient’s longitudinal record. If SkinBit executes its planned expansion from 3 locations in 2026 to 15 by the end of 2027, the company will be testing more than consumer demand. It will be testing whether standardized imaging can become infrastructure inside existing health and wellness businesses.

The $6M therefore buys something more consequential than cameras and square footage. It buys SkinBit the opportunity to prove that its model works repeatedly outside the controlled environment where technology companies tend to look their prettiest.

The financing also belongs inside the larger flow of venture capital funding into AI-enabled healthcare, where investors are increasingly being asked to distinguish between software that demos well and infrastructure that can survive contact with actual clinical workflows.

The Bigger Industry Shift

The most important idea inside SkinBit is almost aggressively simple: healthcare data becomes more valuable when it remembers.

That principle extends well beyond dermatology. Diagnostics, imaging and preventive medicine are increasingly moving from isolated measurements toward longitudinal datasets capable of exposing changes invisible in a single encounter.

SkinBit also offers a useful lesson for AI founders. The strongest healthcare technology does not necessarily eliminate the expert. Sometimes it gives the expert better evidence.

SkinBit has paired computer vision with dermatologist review, built early demand without paid marketing and designed distribution around infrastructure that already exists. Those choices explain more about the company’s investability than the letters A and I ever could.

For DevCuration’s broader Healthcare AI coverage, that is the market signal worth tracking. The interesting companies are increasingly building systems around proprietary data, specialized workflows, human expertise and distribution rather than treating an AI model as the entire business.

The financing is $6M. The larger bet is whether SkinBit can turn repeated images into a durable skin-health record, and whether that record can make change visible while time is still on the patient’s side.